Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

10.1111/ejh.13783

Saved in:
Bibliographic Details
Main Authors: Kulasekararaj, AG, Griffin, M, Langemeijer, S, Usuki, K, Kulagin, A, Ogawa, M, Yu, J, Mujeebuddin, A, Nishimura, JI, Lee, JW, Peffault de Latour, R, 301/302 Study Group, Latypova, A, Barcellini, W, Barraco, F, Beam, D, Bettelheim, P, Borisenkova, E, Brodsky, A, Carnley, B, Cermak, J, Chen, TY, Chew, LP, Chew, TK, Choi, CW, Choi, Y, Chung, JS, De Guibert, S, Devos, T, Dunaev, Y, Dwilewicz-Trojaczek, J, Edahiro, Y, Elykomov, I, Engelberger, MI, Pomponi, F, Fuereder, W, Fujii, N, Fujiwara, S, Galieni, P, Gaya Valls, A, Girault, S, Gomez Almaguer, D, Gonzalez Fernandez, FA, Gritsaev, S, Gunduz, E, Hantaweepant, C, Harada, H, Höglund, M, Huang, WH, Husin, A, Ikezoe, T, Ishiyama, K, Ito, Y, Jang, JH, Jo, DY, Kang, KW, Kennedy, J, Kim, HJ, Kim, JA, Kim, JS, Kimura, F, Kobune, M, Kosugi, H, Kulasekararaj, A, Lai, KM, Larratt, L, Lee, GW, Lee, JH, Lin, CC, Lukina, E, Martynova, E, Matsumura, I, Meike, G, Menosi Gualandro, SF, Minaeva, N, Mori, Y, Morita, K, Morselli Ramalho, FM, Mun, YC, Muus, P, Myasnikov, A, Naito, K, Ninomiya, H, Nogami, A, Notaro, R, Ojeda Gutierrez, E, Okada, M, Okamoto, S, Olkhovik, T, Pane, F, Paquette, R, Park, JS, Peffault de la Tour, R, Piatek, C, Piekarska, A, Pontes Reis, ML, Pospelova, T, Ptushkin, V, Roeth, A
Other Authors: MEDICINE
Format: Article
Published: Wiley 2023
Subjects:
Online Access:https://scholarbank.nus.edu.sg/handle/10635/245612
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
id sg-nus-scholar.10635-245612
record_format dspace
spelling sg-nus-scholar.10635-2456122024-10-26T21:28:51Z Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies Kulasekararaj, AG Griffin, M Langemeijer, S Usuki, K Kulagin, A Ogawa, M Yu, J Mujeebuddin, A Nishimura, JI Lee, JW Peffault de Latour, R 301/302 Study Group Latypova, A Barcellini, W Barraco, F Beam, D Bettelheim, P Borisenkova, E Brodsky, A Carnley, B Cermak, J Chen, TY Chew, LP Chew, TK Choi, CW Choi, Y Chung, JS De Guibert, S Devos, T Dunaev, Y Dwilewicz-Trojaczek, J Edahiro, Y Elykomov, I Engelberger, MI Pomponi, F Fuereder, W Fujii, N Fujiwara, S Galieni, P Gaya Valls, A Girault, S Gomez Almaguer, D Gonzalez Fernandez, FA Gritsaev, S Gunduz, E Hantaweepant, C Harada, H Höglund, M Huang, WH Husin, A Ikezoe, T Ishiyama, K Ito, Y Jang, JH Jo, DY Kang, KW Kennedy, J Kim, HJ Kim, JA Kim, JS Kimura, F Kobune, M Kosugi, H Kulasekararaj, A Lai, KM Larratt, L Lee, GW Lee, JH Lee, JH Lee, JW Lin, CC Lukina, E Martynova, E Matsumura, I Meike, G Menosi Gualandro, SF Minaeva, N Mori, Y Morita, K Morselli Ramalho, FM Mun, YC Muus, P Myasnikov, A Naito, K Ninomiya, H Nogami, A Notaro, R Ojeda Gutierrez, E Okada, M Okamoto, S Olkhovik, T Pane, F Paquette, R Park, JS Peffault de la Tour, R Piatek, C Piekarska, A Pontes Reis, ML Pospelova, T Ptushkin, V Roeth, A MEDICINE Dr Eng Soo Yap breakthrough hemolysis complement inhibitor lactate dehydrogenase paroxysmal nocturnal hemoglobinuria ravulizumab Antibodies, Monoclonal, Humanized Complement C5 Complement Inactivating Agents Hemoglobinuria, Paroxysmal Hemolysis Humans 10.1111/ejh.13783 European Journal of Haematology 109 3 205-214 2023-10-30T03:04:00Z 2023-10-30T03:04:00Z 2022-09-01 2023-10-28T01:13:08Z Article Kulasekararaj, AG, Griffin, M, Langemeijer, S, Usuki, K, Kulagin, A, Ogawa, M, Yu, J, Mujeebuddin, A, Nishimura, JI, Lee, JW, Peffault de Latour, R, 301/302 Study Group, Latypova, A, Barcellini, W, Barraco, F, Beam, D, Bettelheim, P, Borisenkova, E, Brodsky, A, Carnley, B, Cermak, J, Chen, TY, Chew, LP, Chew, TK, Choi, CW, Choi, Y, Chung, JS, De Guibert, S, Devos, T, Dunaev, Y, Dwilewicz-Trojaczek, J, Edahiro, Y, Elykomov, I, Engelberger, MI, Pomponi, F, Fuereder, W, Fujii, N, Fujiwara, S, Galieni, P, Gaya Valls, A, Girault, S, Gomez Almaguer, D, Gonzalez Fernandez, FA, Gritsaev, S, Gunduz, E, Hantaweepant, C, Harada, H, Höglund, M, Huang, WH, Husin, A, Ikezoe, T, Ishiyama, K, Ito, Y, Jang, JH, Jo, DY, Kang, KW, Kennedy, J, Kim, HJ, Kim, JA, Kim, JS, Kimura, F, Kobune, M, Kosugi, H, Kulasekararaj, A, Lai, KM, Larratt, L, Lee, GW, Lee, JH, Lee, JH, Lee, JW, Lin, CC, Lukina, E, Martynova, E, Matsumura, I, Meike, G, Menosi Gualandro, SF, Minaeva, N, Mori, Y, Morita, K, Morselli Ramalho, FM, Mun, YC, Muus, P, Myasnikov, A, Naito, K, Ninomiya, H, Nogami, A, Notaro, R, Ojeda Gutierrez, E, Okada, M, Okamoto, S, Olkhovik, T, Pane, F, Paquette, R, Park, JS, Peffault de la Tour, R, Piatek, C, Piekarska, A, Pontes Reis, ML, Pospelova, T, Ptushkin, V, Roeth, A (2022-09-01). Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. European Journal of Haematology 109 (3) : 205-214. ScholarBank@NUS Repository. https://doi.org/10.1111/ejh.13783 0902-4441 1600-0609 https://scholarbank.nus.edu.sg/handle/10635/245612 Wiley Elements
institution National University of Singapore
building NUS Library
continent Asia
country Singapore
Singapore
content_provider NUS Library
collection ScholarBank@NUS
topic breakthrough hemolysis
complement inhibitor
lactate dehydrogenase
paroxysmal nocturnal hemoglobinuria
ravulizumab
Antibodies, Monoclonal, Humanized
Complement C5
Complement Inactivating Agents
Hemoglobinuria, Paroxysmal
Hemolysis
Humans
spellingShingle breakthrough hemolysis
complement inhibitor
lactate dehydrogenase
paroxysmal nocturnal hemoglobinuria
ravulizumab
Antibodies, Monoclonal, Humanized
Complement C5
Complement Inactivating Agents
Hemoglobinuria, Paroxysmal
Hemolysis
Humans
Kulasekararaj, AG
Griffin, M
Langemeijer, S
Usuki, K
Kulagin, A
Ogawa, M
Yu, J
Mujeebuddin, A
Nishimura, JI
Lee, JW
Peffault de Latour, R
301/302 Study Group
Latypova, A
Barcellini, W
Barraco, F
Beam, D
Bettelheim, P
Borisenkova, E
Brodsky, A
Carnley, B
Cermak, J
Chen, TY
Chew, LP
Chew, TK
Choi, CW
Choi, Y
Chung, JS
De Guibert, S
Devos, T
Dunaev, Y
Dwilewicz-Trojaczek, J
Edahiro, Y
Elykomov, I
Engelberger, MI
Pomponi, F
Fuereder, W
Fujii, N
Fujiwara, S
Galieni, P
Gaya Valls, A
Girault, S
Gomez Almaguer, D
Gonzalez Fernandez, FA
Gritsaev, S
Gunduz, E
Hantaweepant, C
Harada, H
Höglund, M
Huang, WH
Husin, A
Ikezoe, T
Ishiyama, K
Ito, Y
Jang, JH
Jo, DY
Kang, KW
Kennedy, J
Kim, HJ
Kim, JA
Kim, JS
Kimura, F
Kobune, M
Kosugi, H
Kulasekararaj, A
Lai, KM
Larratt, L
Lee, GW
Lee, JH
Lee, JH
Lee, JW
Lin, CC
Lukina, E
Martynova, E
Matsumura, I
Meike, G
Menosi Gualandro, SF
Minaeva, N
Mori, Y
Morita, K
Morselli Ramalho, FM
Mun, YC
Muus, P
Myasnikov, A
Naito, K
Ninomiya, H
Nogami, A
Notaro, R
Ojeda Gutierrez, E
Okada, M
Okamoto, S
Olkhovik, T
Pane, F
Paquette, R
Park, JS
Peffault de la Tour, R
Piatek, C
Piekarska, A
Pontes Reis, ML
Pospelova, T
Ptushkin, V
Roeth, A
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
description 10.1111/ejh.13783
author2 MEDICINE
author_facet MEDICINE
Kulasekararaj, AG
Griffin, M
Langemeijer, S
Usuki, K
Kulagin, A
Ogawa, M
Yu, J
Mujeebuddin, A
Nishimura, JI
Lee, JW
Peffault de Latour, R
301/302 Study Group
Latypova, A
Barcellini, W
Barraco, F
Beam, D
Bettelheim, P
Borisenkova, E
Brodsky, A
Carnley, B
Cermak, J
Chen, TY
Chew, LP
Chew, TK
Choi, CW
Choi, Y
Chung, JS
De Guibert, S
Devos, T
Dunaev, Y
Dwilewicz-Trojaczek, J
Edahiro, Y
Elykomov, I
Engelberger, MI
Pomponi, F
Fuereder, W
Fujii, N
Fujiwara, S
Galieni, P
Gaya Valls, A
Girault, S
Gomez Almaguer, D
Gonzalez Fernandez, FA
Gritsaev, S
Gunduz, E
Hantaweepant, C
Harada, H
Höglund, M
Huang, WH
Husin, A
Ikezoe, T
Ishiyama, K
Ito, Y
Jang, JH
Jo, DY
Kang, KW
Kennedy, J
Kim, HJ
Kim, JA
Kim, JS
Kimura, F
Kobune, M
Kosugi, H
Kulasekararaj, A
Lai, KM
Larratt, L
Lee, GW
Lee, JH
Lee, JH
Lee, JW
Lin, CC
Lukina, E
Martynova, E
Matsumura, I
Meike, G
Menosi Gualandro, SF
Minaeva, N
Mori, Y
Morita, K
Morselli Ramalho, FM
Mun, YC
Muus, P
Myasnikov, A
Naito, K
Ninomiya, H
Nogami, A
Notaro, R
Ojeda Gutierrez, E
Okada, M
Okamoto, S
Olkhovik, T
Pane, F
Paquette, R
Park, JS
Peffault de la Tour, R
Piatek, C
Piekarska, A
Pontes Reis, ML
Pospelova, T
Ptushkin, V
Roeth, A
format Article
author Kulasekararaj, AG
Griffin, M
Langemeijer, S
Usuki, K
Kulagin, A
Ogawa, M
Yu, J
Mujeebuddin, A
Nishimura, JI
Lee, JW
Peffault de Latour, R
301/302 Study Group
Latypova, A
Barcellini, W
Barraco, F
Beam, D
Bettelheim, P
Borisenkova, E
Brodsky, A
Carnley, B
Cermak, J
Chen, TY
Chew, LP
Chew, TK
Choi, CW
Choi, Y
Chung, JS
De Guibert, S
Devos, T
Dunaev, Y
Dwilewicz-Trojaczek, J
Edahiro, Y
Elykomov, I
Engelberger, MI
Pomponi, F
Fuereder, W
Fujii, N
Fujiwara, S
Galieni, P
Gaya Valls, A
Girault, S
Gomez Almaguer, D
Gonzalez Fernandez, FA
Gritsaev, S
Gunduz, E
Hantaweepant, C
Harada, H
Höglund, M
Huang, WH
Husin, A
Ikezoe, T
Ishiyama, K
Ito, Y
Jang, JH
Jo, DY
Kang, KW
Kennedy, J
Kim, HJ
Kim, JA
Kim, JS
Kimura, F
Kobune, M
Kosugi, H
Kulasekararaj, A
Lai, KM
Larratt, L
Lee, GW
Lee, JH
Lee, JH
Lee, JW
Lin, CC
Lukina, E
Martynova, E
Matsumura, I
Meike, G
Menosi Gualandro, SF
Minaeva, N
Mori, Y
Morita, K
Morselli Ramalho, FM
Mun, YC
Muus, P
Myasnikov, A
Naito, K
Ninomiya, H
Nogami, A
Notaro, R
Ojeda Gutierrez, E
Okada, M
Okamoto, S
Olkhovik, T
Pane, F
Paquette, R
Park, JS
Peffault de la Tour, R
Piatek, C
Piekarska, A
Pontes Reis, ML
Pospelova, T
Ptushkin, V
Roeth, A
author_sort Kulasekararaj, AG
title Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
title_short Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
title_full Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
title_fullStr Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
title_full_unstemmed Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
title_sort long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
publisher Wiley
publishDate 2023
url https://scholarbank.nus.edu.sg/handle/10635/245612
_version_ 1821210436643586048